Clarity Pharmaceuticals
Edit

Clarity Pharmaceuticals

https://www.claritypharmaceuticals.com/
Last activity: 08.03.2024
Categories: BioTechDiagnosticsDrugHealthTechMarketMedtechPlatformProductSupplyTechnology
Clarity is a clinical stage radiopharmaceutical company developing next-generation products to address the growing need for the use of radiopharmaceuticals in oncology. Clarity is a global leader in Targeted Copper Theranostics (TCT), developed with its proprietary SAR Technology platform. TCT are the next-generation disruptive platform in radiopharmaceuticals that employ the “perfect pairing” of copper-64 and copper-67 for diagnosis and therapy. TCT deliver a compelling combination of high accuracy and high precision in the treatment of a range of cancers, as well as providing supply and logistical advantages over current theranostics. TCT provide a highly efficacious, scalable, and cost-effective way to expand radiopharmaceuticals into the global oncology market. Clarity has a diverse range of products in clinical trials which address both large indications (prostate cancer and breast cancer) as well as small and orphan indications (neuroendocrine tumours (NETs) and neuroblastoma) of cancer. Our ultimate goal is to improve treatment outcomes for children and adults with cancer.
Followers
100
Mentions
40
Location: Australia, New South Wales, Council of the City of Sydney
Employees: 11-50
Founded date: 2010
Twitter
LinkedIn
Email

Investors 1

Mentions in press and media 40

DateTitleDescriptionSource
08.03.2024Additional COBRA results: SAR-bisPSMA detects lesions in the...Highlights Clarity recently reported that in its diagnostic Phase 1/2 trial, COBRA, 64Cu-SAR-bisPSMA...en.prnasia...
22.12.2023How Commercialisation Australia helped get us off the ground...article-article-body Sydney biotech startup Clarity Pharmaceuticals, which hopes to dramatically imp...smartcompa...
30.11.2023First patient with metastatic prostate cancer to receive 2 d...HIGHLIGHTS Undetectable levels of Prostate Specific Antigen (PSA) have been reported from the first ...en.prnasia...
30.11.2023Registrational Phase III CLARIFY trial in prostate cancer co...SYDNEY, Nov. 30, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a cl...en.prnasia...
29.11.2023Clarity's theranostic prostate cancer trial progresses at th...HIGHLIGHTS Cohort 3 of the theranostic SECuRE trial investigating 64Cu/67Cu-SAR-bisPSMA in metastati...en.prnasia...
07.11.2023Recruitment target achieved for Phase II SAR-Bombesin prosta...SYDNEY, Nov. 7, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a cli...en.prnasia...
26.10.2023Clarity and PSI kick off SAR-bisPSMA Phase IIISYDNEY, Oct. 26, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a cl...en.prnasia...
03.10.2023First patient treated with Cu-67 SAR-Bombesin in theranostic...SYDNEY, Oct. 3, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a cli...en.prnasia...
25.08.2023First participant treated at the highest dose level in Clari...Highlights First participant of cohort 3 in the theranostic SECuRE trial investigating 64Cu/67Cu SAR...en.prnasia...
10.08.2023Clarity's theranostic prostate cancer trial advances to high...Highlights Cohort 2 of the theranostic SECuRE trial investigating 64Cu/67Cu SAR-bisPSMA in metastati...en.prnasia...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In